Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1968 1
1969 1
1974 1
1979 3
1982 1
1983 1
1984 1
1986 1
1989 1
1990 1
1992 1
1993 2
1994 4
1995 2
1996 1
1997 3
1998 1
1999 4
2000 4
2001 6
2002 6
2003 3
2005 4
2006 9
2007 6
2008 4
2009 5
2010 4
2011 12
2012 6
2013 11
2014 7
2015 20
2016 15
2017 12
2018 12
2019 14
2020 13
2021 25
2022 19
2023 23
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
The following term was not found in PubMed: 20Johnsen
Page 1
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, von Bubnoff N, van Linde ME, Lai A, Prager GW, Campone M, Fasolo A, Lopez-Martin JA, Kim TM, Mason WP, Hofheinz RD, Blay JY, Cho DC, Gazzah A, Pouessel D, Yachnin J, Boran A, Burgess P, Ilankumaran P, Gasal E, Subbiah V. Wen PY, et al. Lancet Oncol. 2022 Jan;23(1):53-64. doi: 10.1016/S1470-2045(21)00578-7. Epub 2021 Nov 24. Lancet Oncol. 2022. PMID: 34838156 Clinical Trial.
METHODS: This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial at 27 community and academic cancer centres in 13 countries (Austria, Belgium, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, Sout …
METHODS: This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial at 27 c …
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. Subbiah V, et al. Nat Med. 2023 May;29(5):1103-1112. doi: 10.1038/s41591-023-02321-8. Epub 2023 Apr 14. Nat Med. 2023. PMID: 37059834 Free PMC article. Clinical Trial.
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B. Subbiah V, et al. Ann Oncol. 2022 Apr;33(4):406-415. doi: 10.1016/j.annonc.2021.12.014. Epub 2022 Jan 10. Ann Oncol. 2022. PMID: 35026411 Free PMC article. Clinical Trial.
BACKGROUND: Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an earlier interim analysis of 23 response-assessable patients in the ATC cohort of the phase II Rare Oncolog …
BACKGROUND: Combined therapy with dabrafenib plus trametinib was approved in several countries for treatment of BRAF V600E-mutant anaplastic …
Risk of Aneurysm Rupture (ROAR) study: protocol for a long-term, longitudinal, UK multicentre study of unruptured intracranial aneurysms.
Hall S, Birks J, Anderson I, Bacon A, Brennan PM, Bennett D, Chavredakis E, Critchley G, Dow G, Downer J, Galea J, Grover P, Gurusinghe N, Helmy A, Kounin G, Mukerji N, Patel H, Patel J, Ross N, St George J, Teo M, Tolias CM, Tzerakis N, Uff C, van Beijum J, Veighey K, White E, Whitfield P, Bulters DO; ROAR Investigators. Hall S, et al. BMJ Open. 2023 Mar 16;13(3):e070504. doi: 10.1136/bmjopen-2022-070504. BMJ Open. 2023. PMID: 36927598 Free PMC article.
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. Subbiah V, et al. Lancet Oncol. 2020 Sep;21(9):1234-1243. doi: 10.1016/S1470-2045(20)30321-1. Epub 2020 Aug 17. Lancet Oncol. 2020. PMID: 32818466 Clinical Trial.
METHODS: This study is part of an ongoing, phase 2, open-label, single-arm, multicentre, Rare Oncology Agnostic Research (ROAR) basket trial in patients with BRAF(V600E)-mutated rare cancers. ...The primary endpoint was the overall response rate, which was determined by Re …
METHODS: This study is part of an ongoing, phase 2, open-label, single-arm, multicentre, Rare Oncology Agnostic Research (ROAR) baske …
I Am Woman, Hear Me Roar (in Science).
Loo JA. Loo JA. J Am Soc Mass Spectrom. 2020 Nov 4;31(11):2236. doi: 10.1021/jasms.0c00383. J Am Soc Mass Spectrom. 2020. PMID: 33143430 No abstract available.
Ovarian Cancer Surgery - Heed This LION's Roar.
Eisenhauer EL, Chi DS. Eisenhauer EL, et al. N Engl J Med. 2019 Feb 28;380(9):871-873. doi: 10.1056/NEJMe1900044. N Engl J Med. 2019. PMID: 30811915 No abstract available.
A roar for INCENP.
Greaves S. Greaves S. Nat Cell Biol. 2001 Jan;3(1):E14. doi: 10.1038/35050646. Nat Cell Biol. 2001. PMID: 11146642 Review. No abstract available.
ROAR trial: which treatment is effective after progression?
Sütcüoğlu O, Yücel KB, Üner A, Yazici O, Özdemir N. Sütcüoğlu O, et al. Lancet Oncol. 2022 Mar;23(3):e93. doi: 10.1016/S1470-2045(21)00754-3. Lancet Oncol. 2022. PMID: 35240094 No abstract available.
Rapid Online Assessment of Reading (ROAR): Evaluation of an Online Tool for Screening Reading Skills in a Developmental-Behavioral Pediatrics Clinic.
Barrington E, Sarkisian SM, Feldman HM, Yeatman JD. Barrington E, et al. J Dev Behav Pediatr. 2023 Dec 1;44(9):e604-e610. doi: 10.1097/DBP.0000000000001226. J Dev Behav Pediatr. 2023. PMID: 38016008

This study's purpose was to evaluate ROAR as a screening tool for reading difficulties in a clinical setting. ...The correlation of ROAR standard score with BRS was r = 0.66, p < 0.001. ROC curve analysis with ROAR scores accurately classified poor readers

…
This study's purpose was to evaluate ROAR as a screening tool for reading difficulties in a clinical setting. ...The correlation of …
259 results